GRAIL, Inc.
GRAL · XNASCIK 1699031fmd_1X8Y5KQWPAN3BDEXJKWSKS4ERFServices · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 03, 2022 to Sep 30, 2026, 18 periods
| Line item | FY2022 | FY2023 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | 56 | – | 93 | 126 | 147 |
| Provision for credit losses | – | 0 | – | 0 | 0 |
| Research and development | 330 | – | 339 | 322 | 196 |
| Selling, general and administrative | 296 | – | 363 | 368 | 276 |
| Operating income | (5,443) | – | (1,515) | (2,189) | (562) |
| Interest and investment income | 2 | – | 8 | 27 | 29 |
| Other non-operating income (expense) | 2 | – | 8 | 27 | 28 |
| Income before taxes | (5,441) | – | (1,508) | (2,162) | (535) |
| Income tax expense | (42) | – | (42) | (135) | (126) |
| Net income from continuing operations | (5,399) | – | (1,466) | (2,027) | (408) |
| Net income | (5,399) | – | (1,466) | (2,027) | (408) |